TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4<sup>+</sup>T cells in Preeclampsia Patients

Amin Kamrani(Tabriz University of Medical Sciences), Mehdi Yousefi(Tabriz University of Medical Sciences), Mohammad Sadegh Soltani‐Zangbar(Tabriz University of Medical Sciences), Yousef Yousefzadeh(Tabriz University of Medical Sciences), Mohammad Ali Zolfaghari(Tabriz University of Medical Sciences), Roza Motavalli(Tabriz University of Medical Sciences), Ramin Pourakbari(Tabriz University of Medical Sciences), Shahla Danaii(Academic Center for Education, Culture and Research), Bahman Yousefi(Semnan University of Medical Sciences), Sadaf Shiri(Tabriz University of Medical Sciences), Leili Aghebati‐Maleki(Tabriz University of Medical Sciences), Farhad Jadidi‐Niaragh(Tabriz University of Medical Sciences), Mostafa Haji-Fatahaliha(Tabriz University of Medical Sciences), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Javad Ahmadian Heris(Tabriz University of Medical Sciences), Hossein Samadi Kafil(Tabriz University of Medical Sciences), Asma Emdadi(Tabriz University of Medical Sciences), Ata Mahmoodpoor(Tabriz University of Medical Sciences), Amir Mehdizadeh(Tabriz University of Medical Sciences)
Immunological Investigations
April 15, 2021
10.1080/08820139.2021.1904976
Cited by 25

Related Papers

Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019
|BMJ|2022|849
CAR T cells in solid tumors: challenges and opportunities
|Stem Cell Research & Therapy|2021|573
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312
The paradox of Th17 cell functions in tumor immunity
|Cellular Immunology|2017|222